Correlation between urological drugs with COVID-19
| Medication | Considerations | Drug-drug interaction related to COVID-19 |
|---|---|---|
| α-blockers | Potential to decrease acute respiratory distress syndrome. | None |
| 5α-reductase inhibitors | Mixed reports that they will play a protective or worsening role. | None |
| PDE-5 inhibitors | Theoretically, respiratory symptoms of COVID-19 can be reduced. | Avoid concomitant use with lopinavir/ritonavir. |
PDE-5: phosphodiesterase-5.